Selective analysis of the sentinel node in breast cancer

British Journal of Surgery, 2005

Background: The aim of this study was to validate sentinel node biopsy for axillary staging after the initial learning phase, and to analyse factors associated with false-negative biopsies.

Strahlentherapie und Onkologie, 2000

Background/Purpose: It seems that there exists a specific lymph node center called sentinel node (SN) which appears to be the primary site of metastases. The sentinel node concept (SNC) is fundamentally based on the orderly progression of tumor cells within the lymphatic system. It is the most important new concept in surgical and radiation oncology. The purpose is to present the biological significance, the diagnostic and clinical basis of the sentinel node concept in breast cancer patients. Material and Methods: Lymphoscintigraphy and gamma probe biopsy is necessary to show predictable lymph flow to the regional sentinel node, to multiple sentinel nodes or unpredictable lymph flow to extra-regional sentinel nodes and for performing sentinel node procedure. The standard protocol for the evaluation of the sentinel node metastases consists of extensive histopathological investigation including step Hematoxylin & Eosin (H&E) stained sections and immunohistochemistry. Results: A high rate of success of the identification of the sentinel node for breast cancer was reported. The presence or absence of metastasis in this node is a very accurate predictor of overall nodal status. The temptation to examine the sentinel node with the greatest possible degree of accuracy highlights one of the major problems related to sentinel node biopsy. The success of the sentinel node procedure depends primarily on the adequate functional capacity necessary for sufficient uptake to ensure the accurate identification. In negative sentinel-node patients a complete axillary lymph node dissection is avoidable. In sentinel-node positive patients and clinically negative patients a postoperative radiotherapy would permit an adequate tumor control. The last 2 procedures permit a low morbidity. In the actual TNM clasification it was recently introduced a definition of a "pN0" patient based on sentinel node biopsy. New target volumes are defined for adjuvant radiotherapy or lymphatic basins could be spared from unnecessary irradiation. Conclusion: The sentinel node concept seems to revolutionize the treatment of early breast cancer. Biopsy of the sentinel node is a highly accurate, minimally invasive method of staging patients and can substantially reduce the morbidity and costs of treatment by avoiding unnecessary complete axillary lymph node dissection. The procedure may lead to a more justifiable approach to adjuvant therapy strategies with low complication rates. The identification of the individual lymphatic flow pattern would permit the irradiation of the individual locoregional lymphatic basin.

2010

The concept of breast sentinel node biopsy is based on the assumption that a breast cancer that metastasizes through the lymphatics will initially reach one or a few nodes in the corresponding lymph basin. The status of this or these sentinel node(s) will predict the status of all the other nodes in the basin. The sentinel node can be found stained blue or as being radioactive by injecting blue dye or a radioactive tracer around the tumour. Scintigraphy may further help to localize the sentinel node. The feasibility of the method has been validated by several studies comparing the status of the sentinel node with the node status of the axilla revealed by subsequent axillary clearance. Detection rates of 66-100% and false-negative rates of 17 -0% have been reported. Before the method can be accepted for clinical use, a consensus concerning the accepted false-negative rate has to be reached and has to be shown in practice. From a theoretical point of view, a calculated false-negative risk rate of 2-3% can be accepted.

New England Journal of Medicine, 1998

Annals of Surgical Oncology, 2008

Background: In some patients, the radiocolloid used to perform sentinel lymph node biopsy (SLNB) for breast cancer appears in a number of lymph nodes and in different levels of the axilla. Most positive sentinel lymph node specimens (SLNSs) removed during SLNB are identified in level I of the axilla and within the first 4 SLNSs. Our objective was to verify the staging accuracy of harvesting only the first 4 SLNSs and to determine the relevance of SLNSs that reside in level II of the axilla.

The American Journal of Surgery, 2001

Background: Current literature has suggested that sentinel node biopsy may eventually replace axillary dissection as the nodal staging procedure of choice in early breast cancer. The goals of our study were to determine the accuracy of the sentinel node in predicting axillary nodal status and to evaluate the feasibility of incorporating sentinel node biopsy into a general surgical practice. Methods: Between June 1999 and August 2000, 158 clinically node negative women with a histological diagnosis of T1 or T2 breast cancer were enrolled in the study. Both technetium sulfur colloid radiotracer and isosulfan blue dye were used to guide sentinel node biopsy. Sentinel node biopsy was always followed by a complete axillary dissection. The histopathology of sentinel nodes using serial sectioning and cytokeratin immunohistochemistry was compared with that of the nonsentinel nodes evaluated with routine hematoxylin and eosin stain. Results: The overall sentinel node detection rate was 84% (89 of 106 patients). Sentinel node biopsy was most successful when a combination of radiotracer and dye was used. The staging accuracy of sentinel node biopsy was 98% (87 of 89); the sensitivity of the method was 94% (34 of 36); the false negative rate was 6% (2 of 36); the negative predictive value was 96% (53 of 55); and the rate of metastases to the sentinel node only was 56% (20 of 36). The results varied considerably among surgeons.

International Journal of Breast Cancer, 2011

Background. Sentinel node biopsy (SNB) represents the standard of care in breast cancer axillary evaluation. Our study aims to characterize the patterns of malignant cell distribution within the sentinel nodes (SN). Methods. In a retrospective IRB-approved study, we examined the anatomic location of the nodal area with the highest radioactive signal or most intense blue staining (hot spot) and its distance from the metastatic foci. Results. 58 patients underwent SNB between January 2006 and February 2007. 12 patients with 19 positive SN were suitable for analysis. 4 (21%) metastases were located in the nodal hilum and 15 (79%) in the cortex. 6 (31%) metastases were found adjacent to the hotspot, and 9 (47%) within 4 mm of the hotspot. Conclusions. In our pilot series, SN metastases were within 4 mm of the hotspot in 78% of the cases. Pathologic analysis focused in that area may contribute to the more accurate identification of nodal metastases.

Surgical Oncology Clinics of North America, 2007

The presence or absence of axillary lymph node metastasis in early breast cancer is the most important predictor for survival and recurrence . Sentinel node biopsy (SNB) allows accurate axillary staging of patients with invasive breast cancer and a clinically negative axilla. SNB has less morbidity and fewer complications than traditional axillary lymph node dissection (ALND) . The sentinel lymph node is defined as the first node that receives lymphatic drainage from the affected breast. It is the node most likely to harbor metastases. Examination of sentinel nodes can be extensive because of their relatively small amount of tissue compared with the number of nodes removed by an ALND. SNB has been proven to be safe and effective for patients with relatively small breast cancers (T1 and T2) and clinically negative axillae. False-negative rates initially reported to be between 5% and 15% are now lower, especially in experienced hands. SNB is the preferred method for axillary staging of clinically node-negative patients with breast cancer and has been supported by several consensus conferences such as American Society of Clinical Oncology (ASCO) Guidelines and Recommendations for Sentinel Lymph Node Biopsy in Early-stage Breast

European Journal of Surgical Oncology (EJSO), 2005

Aim. Four-node axillary sampling for breast cancer is an established method of staging the axilla in the United Kingdom. We report the sensitivity of sentinel node (SN) biopsy and compare it with that of four-node sampling.